

Ref. No: 289
From: Public
Date: 25/01/23
Subject: high-cost drugs in ophthalmology

REQUEST

I am researching the usage of high-cost drugs in ophthalmology. Your answers to the following questions will be highly appreciated.

- For the 4 months from September to December 2022, how many patients received the following anti-VEGF treatments for any eye condition:

Treatments	No. of Patients
Aflibercept	350
Bevacizumab	0
Brolucizumab	<5
Dexamethasone	28
Faricimab	0
Ranibizumab – Lucentis	437
Ranibizumab – Ongavia	0

- For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

Treatments	No. of Patients
Aflibercept	39
Bevacizumab	0
Brolucizumab	0
Dexamethasone	<5
Faricimab	0
Ranibizumab – Lucentis	79
Ranibizumab – Ongavia	0

Please note <5 has been added where the number of patients is 5 or less, this information has been redacted to protect patient confidentiality and to ensure that patients cannot be identified.